Analyst Reco. Enfusion, Inc.

Equities

ENFN

US2928121043

Market Closed - Nyse Other stock markets 16:00:02 2024-06-27 EDT			5-day change	1st Jan Change
8.59 ^USD	+2.26%		+5.27%	-11.44%

06-12	Transcript : Enfusion, Inc. Presents at Morgan Stanley US Financials, Payments & CRE Conference 2024, Jun-12-2024 08:00 AM
05-22	Enfusion Insider Sold Shares Worth $325,263, According to a Recent SEC Filing	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Enfusion Insider Sold Shares Worth $325,263, According to a Recent SEC Filing	05-22	MT
BofA Securities Adjusts Price Target on Enfusion to $9 From $8, Maintains Underperform Rating	03-13	MT
Goldman Sachs Downgrades Enfusion to Sell From Neutral, Trims Price Target to $8 From $9	02-28	MT
JPMorgan Downgrades Enfusion to Underweight From Neutral, Cut Price Target to $9 From $11	01-30	MT
UBS Adjusts Enfusion Price Target to $9.50 From $9, Maintains Neutral Rating	11-08	MT
UBS Initiates Coverage on Enfusion With Neutral Rating, $9 Price Target	11-07	MT
Goldman Sachs Adjusts Enfusion's Price Target to $10 From $11.50, Keeps Neutral Rating	23-08-09	MT
Morgan Stanley Adjusts Enfusion Price Target to $11 From $12, Maintains Overweight Rating	23-08-09	MT
Piper Sandler Adjusts Price Target on Enfusion to $9 From $11, Maintains Neutral Rating	23-05-22	MT
Credit Suisse Trims Enfusion's Price Target to $11 From $14, Keeps Neutral Rating	23-05-10	MT
Piper Sandler Starts Enfusion at Neutral With $11 Price Target	23-04-03	MT
JPMorgan Starts Enfusion at Neutral With $12 Price Target	23-03-15	MT
Goldman Sachs Adjusts Price Target on Enfusion to $11.50 From $9.50, Maintains Neutral Rating	23-03-08	MT
Goldman Sachs Adjusts Price Target on Enfusion to $9.50 From $14, Maintains Neutral Rating	23-01-26	MT
BofA Downgrades Enfusion to Underperform From Neutral, Trims Price Target to $10 From $15	23-01-04	MT
Morgan Stanley Upgrades Enfusion to Overweight From Equalweight, Adjusts Price Target to $12 From $13	23-01-03	MT
Goldman Sachs Adjusts Price Target on Enfusion to $14 From $13, Maintains Neutral Rating	22-11-11	MT
BofA Securities Downgrades Enfusion to Neutral From Buy, Adjusts Price Target to $15 From $17	22-10-03	MT
Goldman Sachs Adjusts Enfusion's Price Target to $13 From $12, Maintains Neutral Rating	22-08-10	MT
Morgan Stanley Raises Enfusion's Price Target to $13 From $8, Maintains Equalweight Rating	22-08-10	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Enfusion, Inc.

Equities

ENFN

US2928121043

Analyst Reco.

Filters